Toggle Main Menu Toggle Search

Open Access padlockePrints

Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis

Lookup NU author(s): Professor Anthony De SoyzaORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Neutrophil elastase (NE) activity is increased in bronchiectasis and may play a role in this condition. We wished to determine the effect of AZD9668, a selective oral inhibitor of NE. Efficacy and safety of AZD9668 60 mg twice daily over 4 weeks were evaluated in a randomised, double-blind, placebo-controlled, parallel-group, Phase II, signal-searching study in patients with bronchiectasis. Outcome measures included: waking and post-waking sputum neutrophil counts; lung function tests; 24-h sputum weight; BronkoTest® diary card data; St George's Respiratory Questionnaire for COPD patients (SGRQ-C); sputum NE activity; inflammatory biomarker levels; desmosine levels; adverse events, safety haematology and biochemistry. AZD9668 levels in plasma and sputum were measured to confirm exposure. Thirty-eight patients were randomised: 16 to placebo and 22 to AZD9668. There was no change in sputum neutrophils with AZD9668. Forced expiratory volume in 1 s improved by 100 mL in the AZD9668 group compared with placebo (p = 0.006). Significant changes (defined a priori as p < 0.1) in favour of AZD9668 were also seen in slow vital capacity, plasma interleukin-8, and post-waking sputum interleukin-6 and Regulated on Activation, Normal T-cell Expressed and Secreted levels. Non-significant changes in favour of AZD9668 were seen in other lung function tests, sputum weight and the SGRQ-C. AZD9668 was well tolerated. In this small signal-searching study, 4 weeks' treatment with AZD9668 improved lung function in patients with bronchiectasis and there were trends for reductions in sputum inflammatory biomarkers. Larger studies of longer duration would be needed to confirm the potential benefits of this agent in bronchiectasis.


Publication metadata

Author(s): Stockley R, De Soyza A, Gunawardena K, Perrett J, Forsman-Semb K, Entwistle N, Snell N

Publication type: Article

Publication status: Published

Journal: Respiratory Medicine

Year: 2013

Volume: 107

Issue: 4

Pages: 524-33

Print publication date: 20/02/2013

ISSN (print): 0954-6111

ISSN (electronic): 1532-3064

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/j.rmed.2012.12.009

DOI: 10.1016/j.rmed.2012.12.009

PubMed id: 23433769.


Altmetrics

Altmetrics provided by Altmetric


Funding

Funder referenceFunder name
Grifols
GSK
Novartis
Takeda
Teva UK
Bayer
Boehringer Ingelheim
Chiesi
Forest Labs
HEFCE senior lectureship
Pfizer
NCT00769119AstraZeneca

Share